Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

Evaluation of known oncoantibodies, HER2, p53, and cyclin B1, in prediagnostic breast cancer sera.

Lu H, Ladd J, Feng Z, Wu M, Goodell V, Pitteri SJ, Li CI, Prentice R, Hanash SM, Disis ML.

Cancer Prev Res (Phila). 2012 Aug;5(8):1036-43. doi: 10.1158/1940-6207.CAPR-11-0558. Epub 2012 Jun 19.

2.

Evaluation of serum autoantibodies against tumor-associated antigens as biomarkers in lung cancer.

Li P, Shi JX, Xing MT, Dai LP, Li JT, Zhang JY.

Tumour Biol. 2017 Oct;39(10):1010428317711662. doi: 10.1177/1010428317711662.

PMID:
29022480
3.

Autoantibody detection to tumor-associated antigens of P53, IMP1, P16, cyclin B1, P62, C-myc, Survivn, and Koc for the screening of high-risk subjects and early detection of esophageal squamous cell carcinoma.

Zhou SL, Yue WB, Fan ZM, Du F, Liu BC, Li B, Han XN, Ku JW, Zhao XK, Zhang P, Cui J, Zhou FY, Zhang LQ, Fan XP, Zhou YF, Zhu LL, Liu HY, Wang LD.

Dis Esophagus. 2014 Nov-Dec;27(8):790-7. doi: 10.1111/dote.12145. Epub 2013 Oct 21.

PMID:
24147952
4.

Evaluating Serum Markers for Hormone Receptor-Negative Breast Cancer.

Schummer M, Thorpe J, Giraldez MD, Bergan L, Tewari M, Urban N.

PLoS One. 2015 Nov 13;10(11):e0142911. doi: 10.1371/journal.pone.0142911. eCollection 2015. Erratum in: PLoS One. 2016;11(1):e0147561. Giraldez, Maria [corrected to Giraldez, Maria D].

5.

Preferential autoimmune response in prostate cancer to cyclin B1 in a panel of tumor-associated antigens.

Dai L, Li J, Ortega R, Qian W, Casiano CA, Zhang JY.

J Immunol Res. 2014;2014:827827. doi: 10.1155/2014/827827. Epub 2014 Apr 17.

6.

Tumour-Associated Autoantibodies as Diagnostic Biomarkers for Breast Cancer: A Systematic Review and Meta-Analysis.

Xia J, Shi J, Wang P, Song C, Wang K, Zhang J, Ye H.

Scand J Immunol. 2016 Jun;83(6):393-408. doi: 10.1111/sji.12430. Review.

7.

p53 autoantibodies as potential detection and prognostic biomarkers in serous ovarian cancer.

Anderson KS, Wong J, Vitonis A, Crum CP, Sluss PM, Labaer J, Cramer D.

Cancer Epidemiol Biomarkers Prev. 2010 Mar;19(3):859-68. doi: 10.1158/1055-9965.EPI-09-0880. Epub 2010 Mar 3.

8.

The relationship between serum p53 autoantibodies and characteristics of human breast cancer.

Mudenda B, Green JA, Green B, Jenkins JR, Robertson L, Tarunina M, Leinster SJ.

Br J Cancer. 1994 Jun;69(6):1115-9.

9.

Serum p53 antibodies in correlation to other biological parameters of breast cancer.

Sangrajrang S, Arpornwirat W, Cheirsilpa A, Thisuphakorn P, Kalalak A, Sornprom A, Soussi T.

Cancer Detect Prev. 2003;27(3):182-6.

PMID:
12787724
10.

Application of protein microarrays for multiplexed detection of antibodies to tumor antigens in breast cancer.

Anderson KS, Ramachandran N, Wong J, Raphael JV, Hainsworth E, Demirkan G, Cramer D, Aronzon D, Hodi FS, Harris L, Logvinenko T, LaBaer J.

J Proteome Res. 2008 Apr;7(4):1490-9. doi: 10.1021/pr700804c. Epub 2008 Feb 27.

11.

Anti-p53 antibodies in serum: relationship to tumor biology and prognosis of breast cancer patients.

Kulić A, Sirotković-Skerlev M, Jelisavac-Cosić S, Herceg D, Kovac Z, Vrbanec D.

Med Oncol. 2010 Sep;27(3):887-93. doi: 10.1007/s12032-009-9301-1. Epub 2009 Sep 11.

PMID:
19763913
12.

Usefulness of Salivary and Serum Auto-antibodies Against Tumor Biomarkers HER2 and MUC1 in Breast Cancer Screening.

Laidi F, Bouziane A, Errachid A, Zaoui F.

Asian Pac J Cancer Prev. 2016;17(1):335-9.

14.

Mining the pre-diagnostic antibody repertoire of TgMMTV-neu mice to identify autoantibodies useful for the early detection of human breast cancer.

Mao J, Ladd J, Gad E, Rastetter L, Johnson MM, Marzbani E, Childs JS, Lu H, Dang Y, Broussard E, Stanton SE, Hanash SM, Disis ML.

J Transl Med. 2014 May 10;12:121. doi: 10.1186/1479-5876-12-121.

15.

Autoantibodies to aberrantly glycosylated MUC1 in early stage breast cancer are associated with a better prognosis.

Blixt O, Bueti D, Burford B, Allen D, Julien S, Hollingsworth M, Gammerman A, Fentiman I, Taylor-Papadimitriou J, Burchell JM.

Breast Cancer Res. 2011 Mar 8;13(2):R25. doi: 10.1186/bcr2841.

16.

Evaluation of tumour-associated antigen (TAA) miniarray in immunodiagnosis of colon cancer.

Liu W, Wang P, Li Z, Xu W, Dai L, Wang K, Zhang J.

Scand J Immunol. 2009 Jan;69(1):57-63. doi: 10.1111/j.1365-3083.2008.02195.x.

17.

Serum antibodies against p53 in relation to cancer risk and prognosis in breast cancer: a population-based epidemiological study.

Lenner P, Wiklund F, Emdin SO, Arnerlöv C, Eklund C, Hallmans G, Zentgraf H, Dillner J.

Br J Cancer. 1999 Feb;79(5-6):927-32.

18.

Prognostic significance of serum Her2/neu, BCL2, CA15-3 and CEA in breast cancer patients: a short follow-up.

Samy N, Ragab HM, El Maksoud NA, Shaalan M.

Cancer Biomark. 2010;6(2):63-72. doi: 10.3233/CBM-2009-0119.

PMID:
20571232
19.

Autoimmunity to the M(r) 32,000 subunit of replication protein A in breast cancer.

Tomkiel JE, Alansari H, Tang N, Virgin JB, Yang X, VandeVord P, Karvonen RL, Granda JL, Kraut MJ, Ensley JF, Fernández-Madrid F.

Clin Cancer Res. 2002 Mar;8(3):752-8.

20.

High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer.

Disis ML, Pupa SM, Gralow JR, Dittadi R, Menard S, Cheever MA.

J Clin Oncol. 1997 Nov;15(11):3363-7.

PMID:
9363867

Supplemental Content

Support Center